Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
What is the purpose of this trial?
The purpose of the study is to evaluate safe and efficacious doses of AMG 570 for the treatment of active systemic lupus erythematosus (SLE) in patients who are not responding to the current standard of care. AMG 570 is a bispecific peptide immunoglobulin (Ig) G2 antibody conjugate. This study will help determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects have ongoing disease activity despite treatment with standard of care therapies. If you meet the study requirements and are enrolled, you will be in this study for about 52 weeks.
- Ages18 years - 75 years
- Trial withAmgen, Inc.
- Start Date04/27/2021
- End Date05/19/2022
- Last Updated10/22/2021
- Study HIC#2000027251